Literature DB >> 6620499

The use of imipramine in depressed patients with congestive heart failure.

A H Glassman, L L Johnson, E G Giardina, B T Walsh, S P Roose, T B Cooper, J T Bigger.   

Abstract

Previous studies of left ventricular performance (LVP) in depressed patients receiving tricyclic antidepressants have been performed on patients without severe heart disease. This study reports the effect of imipramine hydrochloride on LVP, assessed by radionuclide angiography, in a group of depressed patients with notable preexisting left ventricular dysfunction. Ejection fraction was measured at rest by first-pass radionuclide angiography before and after treatment with imipramine. Ejection fraction was unchanged during treatment, but seven of 15 patients experienced orthostatic hypotension of such severity that administration of the drug had to be discontinued. Plasma concentrations of the drug were essentially twice those usually seen. It is important to appreciate that although imipramine does not further impair resting LVP, this does not mean it is without risk. The physician must watch carefully for orthostatic hypotension when using imipramine in depressed patients with impaired LVP.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6620499

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  15 in total

Review 1.  CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications.

Authors:  Jang-Ik Lee; Lei Zhang; Angela Y Men; Leslie A Kenna; Shiew-Mei Huang
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

2.  hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine.

Authors:  Ingo Staudacher; Lu Wang; Xiaoping Wan; Sabrina Obers; Wolfgang Wenzel; Frank Tristram; Ronald Koschny; Kathrin Staudacher; Jana Kisselbach; Patrick Koelsch; Patrick A Schweizer; Hugo A Katus; Eckhard Ficker; Dierk Thomas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-12-01       Impact factor: 3.000

3.  Antidepressants and heart disease.

Authors:  M L Orme
Journal:  Br Med J (Clin Res Ed)       Date:  1984-07-07

4.  Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.

Authors:  Sauzanne Khalilieh; Azher Hussain; Diana Montgomery; Vanessa Levine; Peter M Shaw; Inga Bodrug; Lally Mekokishvili; Candice Bailey-Smith; Xiaoli S Glasgow; Amy Cheng; Monika Martinho; Marian Iwamoto
Journal:  Br J Clin Pharmacol       Date:  2018-07-31       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of imipramine and desipramine.

Authors:  F R Sallee; B G Pollock
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

Review 6.  Depression and its treatment in cardiac patients.

Authors:  F Fernandez
Journal:  Tex Heart Inst J       Date:  1993

7.  Mianserin and trazodone for cardiac patients with depression.

Authors:  C Bucknall; D Brooks; P V Curry; P K Bridges; N Bouras; S I Ankier
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Antidepressants do not improve event-free survival in patients with heart failure when depressive symptoms remain.

Authors:  Misook L Chung; Rebecca L Dekker; Terry A Lennie; Debra K Moser
Journal:  Heart Lung       Date:  2013-01-07       Impact factor: 2.210

Review 9.  Antidepressants and falls in the elderly.

Authors:  Adam Darowski; Sally-Ann C F Chambers; David J Chambers
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

10.  Depression in vascular pathologies: the neurologist's point of view.

Authors:  Rita Moretti; Elena Bernobich; Francesca Esposito; Paola Torre; Rodolfo M Antonello; Luisa De Angelis; Giuseppe Bellini
Journal:  Vasc Health Risk Manag       Date:  2011-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.